NR3C1 and prostate neoplasm: One of the mechanisms by which prostate tumors acquire resistance to ADT is via upregulation of the glucocorticoid receptor (GR, NR3C1) [3,4,5], the receptor to which the steroid hormone cortisol and other glucocorticoids bind [6].